Evidence map›Paper›PMID 41236578›Full record

ReviewAmino acids2025

Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy.

Almir Fajkić, Yun Wah Lam, Andrej Belančić

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Amino acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Almir FajkićDepartment of Pathophysiology, Faculty of Medicine, University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina. almir.fajkic@mf.unsa.ba.ORCID http://orcid.org/0000-0002-3722-9701
Yun Wah LamDepartment of Health Sciences, School of Nursing and Health Sciences, Hong Kong Metropolitan University, Hong Kong SAR, China.ORCID http://orcid.org/0000-0001-8929-5965
Andrej BelančićDepartment of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. andrej.belancic@uniri.hr.ORCID http://orcid.org/0000-0001-7848-6600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article introduces a mechanistic framework to reclassify suboptimal responses to GLP-1 receptor agonists. It defines three mechanistic subtypes of incretin resistance-receptor-level, post-receptor, and secretory-highlighting their distinct pathways and therapeutic implications. This model promotes personalized care by moving beyond the oversimplified 'non-responder' classification.

Indexed as

Diabetes Mellitus, Type 2Drug ResistanceGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsHumansGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsGLP-1 receptor agonistIncretin resistanceMechanistic classificationPersonalized medicineTherapeutic variabilityType 2 diabetes mellitus

Identifiers

PMID41236578
PMCPMC12618332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.